Hailing Lu

Dr. Hailing Lu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TWTing Wang
Ting Wang
YXYing Xing
Ying Xing
QMQingwei Meng
Qingwei Meng
HLHailing Lu
Hailing Lu
WLWei Liu
Wei Liu
LCLi Cai
Li Cai
Non-small cell lung cancer (NSCLC) is a devastating disease with a heterogeneous prognosis, and the molecular mechanisms underlying tumor progression remain elusive. Mammalian Eps15 homology domain 1 (EHD1) plays a promotive role in tumor progression, but its role in cancer angiogenesis remains unknown. This study thus explored the role of EHD1 in angiogenesis in NSCLC. The changes in angiogenesis were evaluated through human umbilical vein endothelial cell (HUVEC) proliferation, migration and tube formation assays. The impact of EHD1 on β2-adrenoceptor (β2AR) signaling was evaluated by Western blotting, quantitative real-time polymerase chain reaction (qRT-PCR) analysis, and enzyme-linked immunosorbent assay (ELISA). The interaction between EHD1 and β2AR was confirmed by immunofluorescence (IF) and coimmunoprecipitation (Co-IP) experiments, and confocal microscopy immunofluorescence studies revealed that β2AR colocalized with the recycling endosome marker Rab11, which indicated β2AR endocytosis. Xenograft tumor models were used to investigate the role of EHD1 in NSCLC tumor growth. The microarray analysis revealed that EHD1 was significantly correlated with tumor angiogenesis, and loss- and gain-of-function experiments demonstrated that EHD1 potentiates HUVEC proliferation, migration and tube formation. EHD1 knockdown inhibited β2AR signaling activity, and EHD1 upregulation promoted vascular endothelial growth factor A (VEGFA) and β2AR expression. Interestingly, EHD1 interacted with β2AR and played a novel and critical role in β2AR endocytic recycling to prevent receptor degradation. Aberrant VEGFA or β2AR expression significantly affected EHD1-mediated tumor angiogenesis. The proangiogenic role of EHD1 was confirmed in xenograft tumor models, and immunohistochemistry (IHC) analysis confirmed that EHD1 expression was positively correlated with VEGFA expression, microvessel density (MVD) and β2AR expression in patient specimens. Collectively, the data obtained in this study suggest that EHD1 plays a critical role in NSCLC angiogenesis via β2AR signaling and highlight a potential target for antiangiogenic therapy.

5 October 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JCJinfang Cui
Jinfang Cui
YSYang Song
Yang Song
XHXuejiao Han
Xuejiao Han
JHJing Hu
Jing Hu
YCYanbo Chen
Yanbo Chen
LCLi Cai
Li Cai
Background: The 14-3-3ζ protein, which acts as a putative oncoprotein, has been found to promote the proliferation, metastasis, and chemoresistance of cancer cells in several cancers including lung adenocarcinoma (LUAD); however, its significance in epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) resistance remains unknown. Methods: The Cancer Genome Atlas (TCGA) database was used to determine 14-3-3ζ expression in pancancer and LUAD. 14-3-3ζ and ID1 expression was then examined in clinical LUAD samples by immunohistochemistry (IHC). Lentiviral transfection with 14-3-3ζ-specific small hairpin RNA (shRNA) was used to establish stable 14-3-3ζ knockdown gefitinib-resistant PC9 (PC9/GR) and H1975 cell lines. The effect of 14-3-3ζ knockdown on reversing EGFR-TKI resistance was determined in vitro by Cell Counting Kit-8 (CCK-8), wound healing, Transwell assays, and flow cytometry. A xenograft tumor model was established to evaluate the role of 14-3-3ζ in EGFR-TKI resistance. Microarray analysis results showed multiple pathways regulated by 14-3-3ζ-shRNA. Results: In the present study, we demonstrated that based on the TCGA, pancancer and LUAD 14-3-3ζ expression was elevated and predicted unfavorable prognosis. In addition, high 14-3-3ζ expression was associated with advanced T stage, TNM stage, presence of lymph node metastasis and, importantly, poor treatment response to EGFR-TKIs in LUAD patients with EGFR-activating mutations. 14-3-3ζ shRNA sensitized EGFR-TKI-resistant human LUAD cells to gefitinib and reversed epithelial-to-mesenchymal transition (EMT). After 14-3-3ζ depletion, bone morphogenetic protein (BMP) signaling activation was decreased in EGFR-TKI-resistant cells in microarray analysis, which was further validated by Western blot analysis. Furthermore, the expression of 14-3-3ζ positively correlates with ID1 expression in human EGFR-mutant LUAD patient samples. In vivo, there was a reduction in the tumor burden in mice treated with 14-3-3ζ shRNA and gefitinib compared to mice treated with gefitinib alone. Conclusion: Our work uncovers a hitherto unappreciated role of 14-3-3ζ in EGFR-TKI resistance. This study might provide a potential therapeutic approach for treating LUAD patients harboring EGFR mutations.

17 February 2020 in Research Square
Verified
Preprint
Open access
PDF file
JCJinfang Cui
Jinfang Cui
YSYang Song
Yang Song
XHXuejiao Han
Xuejiao Han
JHJing Hu
Jing Hu
YCYanbo Chen
Yanbo Chen
LCLi Cai
Li Cai
Background: 14-3-3ζ protein which acts as a putative oncoprotein has been found to promote proliferation, metastasis and chemoresistance of cancer cells in several cancers including lung adenocarcinoma (LUAD), however, its significance in epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance remains unknown. Methods: The Cancer Genome Atlas (TCGA) database was used to determine 14-3-3ζ expression in pan-cancer and LUAD. 14-3-3ζ and ID1 expression was then examined in clinical LUAD samples by immunohistochemistry (IHC). Lentiviral transfection with 14-3-3ζ-specific shRNA was used to establish stable 14-3-3ζ knockdown gefitinib resistant PC9 (PC9/GR) and H1975 cell lines. The effect of 14-3-3ζ knockdown on reversing EGFR-TKI resistance was determined in vitro by CCK-8, wound healing, transwell assays and flow cytometry. A xenograft tumor model was established to evaluate the role of 14-3-3ζ in EGFR-TKI resistance. Microarray analysis results showed the multiple pathways regulated by 14-3-3ζ-shRNA. Results: In the present study, we firstly demonstrated that 14-3-3ζ expression was elevated and predicted unfavourable prognosis in pan-cancer including LUAD based on TCGA. In addition, high 14-3-3ζ expression was significantly associated with advanced T stage, TNM stage, present of lymph node metastasis and, importantly, poor treatment response to EGFR-TKI in LUAD patients with EGFR-activating mutations. 14-3-3ζ shRNA significantly sensitized EGFR-TKI-resistant human LUAD cells to gefitinib and, notably, reversed epithelial-to-mesenchymal transition (EMT). BMP signaling activation was decreased in EGFR-TKI resistant cells followed by 14-3-3ζ depletion in microarray analysis, which was further validated by Western blot analysis. Furthermore, the expression of 14-3-3ζ positively correlates with ID1 expression in human EGFR-mutant LUAD patient samples. In vivo , 14-3-3ζ shRNA and gefitinib treatment resulted in a significant reduction in the tumor burden compared to that treated with gefitinib alone. Conclusion: Our work uncovers a hitherto unappreciated role of 14-3-3ζ in EGFR-TKI resistance. This study might provide a potential therapeutic approach for treating LUAD patients harboring EGFR mutations.

1 November 2025 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
MGMingyuan Guo
Mingyuan Guo
JZJun Zhu
Jun Zhu
XDXiaoman Duan
Xiaoman Duan
PRPengyue Ren
Pengyue Ren
HWHaitao Wang
Haitao Wang
YZYanbin Zhao
Yanbin Zhao
Background: Accurate survival prediction is critical for optimizing clinical management in small cell lung cancer (SCLC) patients with initial brain metastasis (BM). This study aims to develop a machine learning (ML)-based prognostic model to improve survival prediction, thereby enhancing clinical decision-making and treatment outcomes. Methods: Data on SCLC patients with initial BM were extracted from the Surveillance, Epidemiology, and End Results (SEER) database for the period from 2010 to 2020 and split into training (70%) and testing (30%) sets. We used COX proportional hazards regression model to select modeling features in the training set. Four ML methods, including least absolute shrinkage and selection operator (LASSO), random forest (RF), eXtreme Gradient Boosting (XGBoost), and gradient boosting machine (GBM), were used to establish prognostic models and validated by both the SEER database and patients from Harbin Medical University Cancer Hospital. Model performance was evaluated using area under the curve (AUC) values, accuracy and F1 scores. Furthermore, we conducted a prioritization of the importance of features by SHapley Additive exPlanations (SHAP) at various time points. Results: A total of 4,227 patients were enrolled in the SEER database, with 2,958 cases allocated to the training set and 1,269 to the testing set. Based on the results of univariate and multivariate COX regression analyses, we identified age, sex, marital, primary tumor size, N stage, bone metastasis, liver metastasis, lung metastasis, months from diagnosis to therapy, surgery, radiotherapy, and chemotherapy as model features. The LASSO model outperformed other models, with AUCs of 0.771, 0.724, 0.753, 0.718 at 6 months, 1 year, 2 years, and 3 years in the testing set, and 0.801, 0.763, 0.838, and 0.900 in the external validation set. Additionally, feature importance analysis consistently identified liver metastasis (highest rank), surgery, radiotherapy, lung metastasis, and chemotherapy as key predictors across all time points. Conclusions: The LASSO model demonstrated high accuracy in predicting survival for SCLC patients with initial BM, particularly in external validation. This model may provide valuable prognostic insights for personalized treatment strategies.